Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.46 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25124976 | 1.00 | SOS1 (0.46) | SOS1SOS2CYP1A2 | |
| SCHEMBL21210664 | 0.94 | SOS1 (0.48) | SOS1SOS2 | |
| SCHEMBL18806109 | 0.88 | SOS1 (0.35) | SOS1SOS2CYP1A2 | |
| SCHEMBL24720256 | 0.88 | SOS1 (0.39) | SOS1SOS2 | |
| SCHEMBL27443832 | 0.86 | SOS1 (0.52) | SOS1SOS2 | |
| SCHEMBL24568091 | 0.86 | SOS1 (0.41) | SOS1SOS2 | |
| SCHEMBL23338573 | 0.85 | SOS1 (0.46) | SOS1SOS2 | |
| SCHEMBL17789639 | 0.82 | SOS1 (0.45) | SOS1SOS2 | |
| SCHEMBL27275379 | 0.81 | SOS1 (0.37) | SOS1SOS2CYP1A2 | |
| SCHEMBL24576859 | 0.80 | SOS1 (0.44) | SOS1SOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179059-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-06-05 | — | — | US | disclosed |
| US-12162870-B2 | Anticancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-10 | — | — | US | disclosed |
| US-20230112485-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| US-20230025178-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-01-26 | — | — | US | disclosed |
| US-10640500-B2 | Tetrahydropyrazolopyrimidine compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179059-A1 | ANTICANCER COMPOUNDS | BET1, BRD4, BICRA | SOS1 3905/4885SOS2 4129/4885CYP1A2 4254/4885 |
| US-20230025178-A1 | ANTICANCER COMPOUNDS | BET1, BRD4, BICRA | SOS1 3905/4885SOS2 4129/4885CYP1A2 4254/4885 |
| US-10640500-B2 | Tetrahydropyrazolopyrimidine compounds | SSB, TLR8, TLR9 | SOS1 3062/4885SOS2 2317/4885CYP1A2 4445/4885 |
| US-20230112485-A1 | THERAPEUTIC COMPOUNDS | BRDT, BRPF3, SNRPE | SOS1 3407/4885SOS2 3429/4885CYP1A2 4879/4885 |
| US-12162870-B2 | Anticancer compounds | BET1, BRD4, BICRA | SOS1 3905/4885SOS2 4129/4885CYP1A2 4254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.